Name: Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer (en Inglés)
Price: 70074.00 ARS
Availability: InStock
Author: Adunlin, Georges
ISBN: 9783036547077

portada Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer (en Inglés)

Formato

Libro Físico

Ilustrado por

Georges Adunlin

Editorial

Mdpi AG

Autor

Adunlin, Georges

Idioma

Inglés

N° páginas

204

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 1.8 cm

Peso

0.64 kg.

ISBN13

9783036547077

Categorías

Oncología
Especialidades de enfermería

Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer (en Inglés)

Georges Adunlin (Ilustrado por) · Mdpi AG · Tapa Dura

Libro Nuevo

$ 70.074

$ 116.790

Ahorras: $ 46.716

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 25 de Junio y el Martes 09 de Julio.

Lo recibirás en cualquier lugar de Argentina entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer (en Inglés)"

Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.